ClinVar Miner

Submissions for variant NM_000352.6(ABCC8):c.4198G>A (p.Gly1400Arg)

gnomAD frequency: 0.00004  dbSNP: rs137852676
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000029263 SCV000051909 likely pathogenic Familial hyperinsulinism 2022-05-06 criteria provided, single submitter clinical testing Variant summary: ABCC8 c.4198G>A (p.Gly1400Arg) results in a non-conservative amino acid change located in the ABC transporter-like, ATP-binding domain (IPR003439) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.5e-05 in 195184 control chromosomes. c.4198G>A has been reported in the literature as a heterozygous and compound heterozygous genotype in individuals affected with focal and diffuse forms of Congenital Hyperinsulinism (example, Stanley_2004, Suchi_2006, Greer_2007, Ellard_2007, Rafiq_2008, Sandal_2009, Dastamani_2019). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic.
Invitae RCV001390783 SCV001592625 pathogenic not provided 2023-12-12 criteria provided, single submitter clinical testing This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 1400 of the ABCC8 protein (p.Gly1400Arg). This variant also falls at the last nucleotide of exon 34, which is part of the consensus splice site for this exon. This variant is present in population databases (rs137852676, gnomAD 0.001%). This missense change has been observed in individual(s) with autosomal recessive neonatal diabetes and congenital hyperinsulinism (PMID: 17668386, 19475716). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. This variant is also known as Gly1401Arg. ClinVar contains an entry for this variant (Variation ID: 35616). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects ABCC8 function (PMID: 22802590, 31464105). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.
Myriad Genetics, Inc. RCV002326685 SCV002060366 likely pathogenic Hyperinsulinemic hypoglycemia, familial, 1 2021-10-20 criteria provided, single submitter clinical testing NM_000352.3(ABCC8):c.4198G>A(G1400R) is a missense variant classified as likely pathogenic in the context of ABCC8-related hyperinsulinism. G1400R has been observed in cases with relevant disease (PMID: 31464105, 23275527, 17378627, 19475716, 17919176, 30114684). Functional assessments of this variant are available in the literature (PMID: 22802590, 31464105). G1400R has been observed in population frequency databases (gnomAD: NFE 0%). In summary, NM_000352.3(ABCC8):c.4198G>A(G1400R) is a missense variant that has been observed more frequently in cases with the relevant disease than in healthy populations. Please note: this variant was assessed in the context of healthy population screening.
Genetic Services Laboratory, University of Chicago RCV001390783 SCV002069224 pathogenic not provided 2018-07-27 criteria provided, single submitter clinical testing
Revvity Omics, Revvity Omics RCV001390783 SCV003815543 likely pathogenic not provided 2022-06-07 criteria provided, single submitter clinical testing
Broad Institute Rare Disease Group, Broad Institute RCV003321485 SCV004026508 likely pathogenic Hyperinsulinemic hypoglycemia, familial, 1 2023-08-16 criteria provided, single submitter curation The p.Gly1400Arg variant in ABCC8 has been reported in at least 6 individuals with hyperinsulinemic hypoglycemia (PMID: 16357843, 17378627, 19475716, 23275527, 30114684, 31464105), and has been identified in 0.004% (4/98246) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs137852676). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. Of the 6 affected individuals, at least 2 were compound heterozygotes that carried a reported pathogenic variant in trans, which increases the likelihood that the p.Gly1400Arg variant is pathogenic (Variation ID: 553929; PMID: 16357843, 19475716). In vitro functional studies provide some evidence that the p.Gly1400Arg variant may slightly impact protein function (PMID: 31464105, 22802590). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic for autosomal recessive hyperinsulinemic hypoglycemia. ACMG/AMP Criteria applied: PM3_strong, PP3, PM2_supporting, PS3_supporting (Richards 2015).
Baylor Genetics RCV003466873 SCV004193550 likely pathogenic Type 2 diabetes mellitus 2023-10-26 criteria provided, single submitter clinical testing
OMIM RCV000009657 SCV000029875 pathogenic Diabetes mellitus, permanent neonatal 3 2007-08-01 no assertion criteria provided literature only
Natera, Inc. RCV001277179 SCV001464077 likely pathogenic Hereditary hyperinsulinism 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.